UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 229

Sortiert nach

Axitinib for the Management of Metastatic Renal Cell Carcinoma

Drugs in R&D, 2011-06, Vol.11 (2), p.113-126

2011

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

BMC cancer, 2018-12, Vol.18 (1), p.1292-1292, Article 1292

2018

Link zum Volltext

Verfügbarkeit prüfen

Tyro-3 family receptors are essential regulators of mammalian spermatogenesis

Nature (London), 1999-04, Vol.398 (6729), p.723-728

1999

Link zum Volltext

Verfügbarkeit prüfen

Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma

Oncology (Williston Park, N.Y.), 2006-05, Vol.20 (6 Suppl 5), p.19

2006

Link zum Volltext

Verfügbarkeit prüfen

Response: Re: Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

JNCI : Journal of the National Cancer Institute, 2011-10, Vol.103 (20), p.1558-1558

2011

Link zum Volltext

Verfügbarkeit prüfen

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients

Scientific reports, 2016-07, Vol.6 (1), p.29506-29506, Article 29506

2016

Link zum Volltext

Verfügbarkeit prüfen

Which patients with renal cancer may benefit from sunitinib therapy?

Therapeutic advances in medical oncology, 2010-03, Vol.2 (2), p.69-74

2010

Link zum Volltext

Verfügbarkeit prüfen

Editorial

Current opinion in oncology, 2010-09, Vol.22 (5), p.461

Gore, Martin

2010

Link zum Volltext

Verfügbarkeit prüfen

Editorial. Managing patients with ovarian cancer, and other themes

Current opinion in oncology, 2010-09, Vol.22 (5), p.461-461

Gore, Martin

2010

Link zum Volltext

Verfügbarkeit prüfen

Optimal approach for melanoma

European journal of cancer supplements, 2013-09, Vol.11 (2), p.80-80

Gore, Martin

2013

Link zum Volltext

Verfügbarkeit prüfen

Less Is More – A Systematic Review of the Outcomes of Radical Versus Conservative Primary Resection in Anorectal Melanoma

European journal of surgical oncology, 2020-02, Vol.46 (2), p.e13-e13

2020

Link zum Volltext

Verfügbarkeit prüfen

Prevalence and clinical implications of mismatch repair (MMR) deficiency in unselected non-serous epithelial ovarian cancer (EOC) patients (pts)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1521-1521

2019

Link zum Volltext

Verfügbarkeit prüfen

Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution

Nature communications, 2015-03, Vol.6 (1), p.6336-6336, Article 6336

2015

Link zum Volltext

Verfügbarkeit prüfen

Part II: Chemotherapy for epithelial ovarian cancer-treatment of rcurrent disease

The lancet oncology, 2002-09, Vol.3 (9), p.537-545

2002

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis

Clinical cancer research, 2016-07, Vol.22 (13), p.3172-3181

2016

Link zum Volltext

Verfügbarkeit prüfen

So you want to be ... a medical oncologist

British journal of hospital medicine (London, England : 2005), 2009-10, Vol.70 (10), p.M160

Gore, Martin

2009

Link zum Volltext

Verfügbarkeit prüfen

Caelyx-induced unilateral erythrodysesthaesia secondary to venous thromboembolism

EJD. European journal of dermatology, 2017-05, Vol.27 (3), p.321-322

2017

Link zum Volltext

Verfügbarkeit prüfen

The UK 'postcode lottery' in renal cell carcinoma

Nature reviews. Urology, 2009-12, Vol.6 (12), p.636-638

2009

Link zum Volltext

Verfügbarkeit prüfen

Long-term response to sunitinib treatment in metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.598-598

2016

Link zum Volltext

Verfügbarkeit prüfen

ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS4583-TPS4583

2016

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9501-9501

2017

Link zum Volltext

Verfügbarkeit prüfen

A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) previously treated with antiangiogenic therapy

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS4592-TPS4592

2013

Link zum Volltext

Verfügbarkeit prüfen

Defining the mechanisms of response and resistance to anti-PD-1 therapy: An exploratory phase II study of pembrolizumab in advanced melanoma (ADAPTeM)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS9599-TPS9599

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 229

Suche als RSS-Feed

Aktive Filter

ThemaCancer

ThemaLife Sciences & Biomedicine

ThemaMedical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(185)
Mit Volltextzugriff
(212)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(41)
Male
(20)
Female
(19)
Science & Technology
(15)
Adult
(14)
Middle Aged
(13)
Aged
(11)
Melanoma
(11)
Multidisciplinary Sciences
(11)
Science & Technology - Other Topics
(11)
Oncology
(6)
Ovarian Cancer
(5)
Treatment Outcome
(5)
Aged, 80 And Over
(4)
Antineoplastic Agents - Adverse Effects
(4)
Antineoplastic Agents - Therapeutic Use
(4)
Care And Treatment
(4)
Chemotherapy
(4)
Medicine
(4)
Medicine & Public Health
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Axitinib for the Management of Metastatic Renal Cell Carcinoma

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Tyro-3 family receptors are essential regulators of mammalian spermatogenesis

Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma

Response: Re: Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients

Which patients with renal cancer may benefit from sunitinib therapy?

Editorial

Editorial. Managing patients with ovarian cancer, and other themes

Optimal approach for melanoma

Less Is More – A Systematic Review of the Outcomes of Radical Versus Conservative Primary Resection in Anorectal Melanoma

Prevalence and clinical implications of mismatch repair (MMR) deficiency in unselected non-serous epithelial ovarian cancer (EOC) patients (pts)

Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution

Part II: Chemotherapy for epithelial ovarian cancer-treatment of rcurrent disease

A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis

So you want to be ... a medical oncologist

Caelyx-induced unilateral erythrodysesthaesia secondary to venous thromboembolism

The UK 'postcode lottery' in renal cell carcinoma

Long-term response to sunitinib treatment in metastatic renal cell carcinoma (mRCC)

ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models: Vessel co-option in lung metastases

A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) previously treated with antiangiogenic therapy

Defining the mechanisms of response and resistance to anti-PD-1 therapy: An exploratory phase II study of pembrolizumab in advanced melanoma (ADAPTeM)

Aktive Filter

Suchergebnisse filtern